“Dr. Alan So graduated with a medical degree from the University of Alberta. He completed his residency at Dalhousie University. Dr. Alan So finished his uro-oncology fellowship at Vancouver Prostate Centre/the University of British Columbia. During his post-doctoral fellowship, he published more than ten peer-reviewed papers. Dr. So’s current research focuses on the study of the development of novel therapeutics for bladder cancer and the determination of the functional role of GLI1/2 in the progression of prostate cancer to its lethal stage of androgen independence. He has characterized the functional role of different survival genes (including clusterin and Hsp27) in other tumour models (prostate, breast, lung, and bladder) in cancer progression. Dr. Alan So is a member of the National Cancer Institute of Canada GU Clinical Trials Group and the Canadian Uro-Oncology Group.”
Read more
